All In Biotech

Drug Trial Radar · NCT05683496

Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)

A Phase 1/2, Adaptive, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of Lonigutamab in Subjects With Thyroid Eye Disease (TED)

Last checked: Nov 19, 2026Latest source record: Jul 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

31

Actual

Start

Feb 14, 2023

Primary completion

May 26, 2025

Study completion May 26, 2025

Sponsor

Lead sponsor
ACELYRIN Inc.Industry
Sponsor type
Industry
First posted
Jan 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1/2, multicenter, multiple dose clinical study designed to evaluate lonigutamab in subjects with TED.

Conditions

  • Thyroid Eye Disease

Interventions

  • lonigutamabDrug

    subcutaneous injection

  • PlaceboDrug

    subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and characterization of nonserious treatment emergent adverse events (TEAEs)Time frame: Day 1 to Day 169
  2. Incidence and characterization of serious treatment emergent adverse events (TEAEs)Time frame: Day 1 to Day 169

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • Clinical Research Site

    Jacksonville, Florida

  • Clinical Research Site

    Atlanta, Georgia

  • Clinical Research Site

    Ann Arbor, Michigan

  • Clinical Research Site

    East Setauket, New York

  • Clinical Research Site

    New York, New York

  • Clinical Research Site

    Morgantown, West Virginia

  • Clinical Research Site

    Sydney, New South Wales, Australia

  • Clinical Research Site

    Woolloongabba, Queensland, Australia

  • Clinical Research Site

    Adelaide, South Australia, Australia

  • Clinical Research Site

    East Melbourne, Victoria, Australia

  • Clinical Research Site

    Nedlands, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.